Mereo BioPharma (MREO) Share-based Compensation (2023 - 2026)

Mereo BioPharma (MREO) has 4 years of Share-based Compensation data on file, last reported at $1.6 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $1.6 million, down 29.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.9 million (down 9.08% YoY), and the FY2025 annual result was $7.6 million, up 2.81% from the prior year.
• Share-based Compensation advanced to $1.6 million in Q1 2026 per MREO's latest filing, from $1.5 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $2.3 million in Q1 2025 and troughed at $815000.0 in Q4 2023.
• A 4-year average of $1.7 million and a median of $1.6 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2026: Share-based Compensation jumped 121.42% in 2024, then fell 29.54% in 2026.
• A 4-year view of Share-based Compensation shows it stood at $815000.0 in 2023, then soared by 85.89% to $1.5 million in 2024, then grew by 1.85% to $1.5 million in 2025, then grew by 4.02% to $1.6 million in 2026.
• Business Quant data shows MREO's Share-based Compensation at $1.6 million in Q1 2026, $1.5 million in Q4 2025, and $1.7 million in Q3 2025.